文献速递垂体与肾上腺疾病

单侧原发性醛固酮增多症排除试验(ExcluPA)研究

Exclusion Tests in Unilateral Primary Aldosteronism (ExcluPA) Study.
PubMed 文献 · J Clin Endocrinol Metab · 2023-01-01

该研究通过两阶段Meta分析评估排除试验对单侧原发性醛固酮增多症的诊断准确性,纳入31个数据集共4242例患者。结果显示醛固酮肾素比值、卡托普利试验和盐水输注试验的汇总AUC无差异,但卡托普利试验和盐水输注试验的高准确性源于高预检概率,并未在醛固酮肾素比值基础上提供额外诊断增益,因此系统性使用这些排除试验缺乏证据支持。

要点

  • 在4242例患者中,醛固酮肾素比值、卡托普利试验和盐水输注试验的汇总AUC分别为0.95、0.92和0.96,无差异。
  • 卡托普利试验和盐水输注试验的高诊断准确性源于入选患者醛固酮肾素比值升高、单侧原发性醛固酮增多症预检概率高。
  • 卡托普利试验和盐水输注试验均未在醛固酮肾素比值基础上提供诊断增益,系统性使用缺乏证据支持。

核心结论

  • 卡托普利试验和盐水输注试验未在醛固酮肾素比值基础上提供诊断增益,系统性使用这些排除试验缺乏证据支持。

研究设计与样本

  • 检索PubMed、EMBASE、Web of Science和Cochrane Library数据库1970年1月1日至2021年12月31日发表的研究,按PRISMA方法提取数据。
  • 采用两阶段Meta分析,分别基于探索性和验证性阶段,以单侧原发性醛固酮增多症诊断为参考标准。
  • 共纳入31个数据集、4242例符合预设纳入标准的患者。

主要发现

  • 醛固酮肾素比值、卡托普利试验和盐水输注试验的汇总sAUROC分别为0.95(95%CI 0.92-0.98)、0.92(95%CI 0.88-0.97)和0.96(95%CI 0.94-0.99),三者间无差异。
  • 氟氢可的松抑制试验和呋塞米直立试验各仅纳入1项研究,无法获得可靠信息。

关键数值与推荐

  • 醛固酮肾素比值汇总sAUROC为0.95(95%CI 0.92-0.98)。
  • 卡托普利试验汇总sAUROC为0.92(95%CI 0.88-0.97)。
  • 盐水输注试验汇总sAUROC为0.96(95%CI 0.94-0.99)。

临床怎么用

  • 原文结论认为,现有证据不支持在临床实践中系统性使用卡托普利试验和盐水输注试验作为排除试验。

局限性

  • 氟氢可的松抑制试验和呋塞米直立试验各仅纳入1项研究,无法获得可靠信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Determining the diagnostic accuracy of "exclusion" tests for primary aldosteronism (PA) compared to the aldosterone to renin ratio (ARR) is fundamental to avoid invasive subtyping in false-positive patients at screening. OBJECTIVE: To assess the accuracy of exclusion tests for PA using the diagnosis of unilateral PA as reference. METHODS: PubMed, EMBASE, Web of Science, and Cochrane Library databases were searched for studies published from January 1, 1970, to December 31, 2021, meeting tight quality criteria. Data were extracted following the PRISMA methodology. We performed a two-stage meta-analysis that entailed an exploratory and a validation phase based on a "golden" or "gold" diagnostic standard, respectively. Pooled specificity, negative likelihood ratio, diagnostic odds ratio, and summary area under the ROC curve (sAUROC) were calculated to analyze the accuracy of exclusion tests. RESULTS: A meta-analysis of 31 datasets comprising a total of 4242 patients fulfilling the predefined inclusion criteria found that pooled accuracy estimates (sAUROC) did not differ between the ARR (0.95; 95% CI, 0.92-0.98), the captopril challenge test (CCT) (0.92; 95% CI, 0.88-0.97), and the saline infusion test (SIT) (0.96; 95% CI, 0.94-0.99). Solid information could not be obtained for the fludrocortisone suppression test and the furosemide upright test, which were assessed in only 1 study each. CONCLUSION: The apparently high diagnostic accuracy of the CCT and the SIT was due to the selection of patients with an elevated ARR and thus a high pretest probability of unilateral PA; however, neither test furnished a diagnostic gain over the ARR. Therefore, the systematic use of these exclusion tests in clinical practice is not justified by available evidence.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Zhu R, Shagjaa T, Rossitto G, et al. Exclusion Tests in Unilateral Primary Aldosteronism (ExcluPA) Study. J Clin Endocrinol Metab. 2023. PMID: 36373399. doi:10.1210/clinem/dgac654

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。